Program
WRN Inhibitor RO7589831
Its studies are mostly in Colorectal Neoplasms, Hereditary Nonpolyposis · Colorectal Neoplasms, led by Bayer.
Furthest: phase 2, since Sep 2, 20262 company-led studies, 2 open or runningNext primary completion: May 31, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 22 open or running | phase 2since Sep 2, 2026 | Aug 16, 2023 | May 31, 2027phase 1 · NCT06004245 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 16, 2023First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT06004245 · 280 planned · United States, Australia, Belgium and more
- Sep 2, 2026Phase 2 study in Colorectal Neoplasms, Hereditary NonpolyposisPhase 2 reachedNCT07811193 · 140 planned · United States, Argentina, Belgium and more
Ahead
- May 31, 2027Primary completion: phase 1 study in Colorectal NeoplasmsNCT06004245
- Jun 30, 2028Primary completion: phase 2 study in Colorectal Neoplasms, Hereditary NonpolyposisNCT07811193
TargetBeta
WRN →read by rule
“An orally bioavailable and small molecule inhibitor of Werner syndrome ATP-dependent helicase (WRN; RecQ protein-like 2; Werner syndrome protein), ”NCIt, by rule
Other programs on WRN
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| WRN Inhibitor GSK4418959rule | GlaxoSmithKline | phase 2 | 1 |
| WRN Inhibitor NDI-219216rule | nimbus-wadjet-inc | phase 2 | 1 |
| WRN Inhibitor EIK1005rule | eikon-therapeutics | phase 2 | 1 |
| WRN Inhibitor MOMA-341rule | moma-therapeutics | phase 1 | 1 |
| WRN Inhibitor AMG 436rule | Amgen | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07811193Colorectal Neoplasms, Hereditary Nonpolyposis · United States, Argentina, Belgium and more | 2 | Recruiting | Jun 30, 2028 | 140 |
| NCT06004245Colorectal Neoplasms · United States, Australia, Belgium and more | 1 | Recruiting | May 31, 2027 | 280 |
How it is read
Names in the registry
- “VVD-133214”, 2 entries
Conditions, from the studies’ own filings
- Colorectal Neoplasms, Hereditary Nonpolyposis, 1 study
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.